Prognostic tests for development of dermal stretch marks and implications for the preventive treatment thereof
View Patent ↗Various methods of assessing the regenerative potential of dermal tissue in a patient may be determined and methods to determine the potential development of stretch marks in a patient are provided. Through the analysis of a series of dermal tissue samples, a method of monitoring the aging process of the dermal tissue of a patient is possible. Damaged or stretched marked skin may also be used in the development of various diagnostic therapies relating to the inducement of the extracellular matrix components of the skin due to the loss of elastic fibers generally found in stretch marked skin.
1. A method of screening for the increased potential for the development of new stretch marks in a human patient who already has stretch marks in one area of the skin comprising:
establishing a total extracellular matrix protein content and a total fibroblast DNA content for normal dermal tissue from a control human subject;
obtaining a sample of dermal tissue from non-stretch marked skin of said human patient;
determining the total extracellular matrix protein content and the total fibroblast DNA content from said sample of dermal tissue from the human patient;
comparing the extracellular matrix protein content and the fibroblast DNA content from said sample of dermal tissue from said human patient with the extracellular matrix protein content and the fibroblast DNA content for normal dermal tissue from said control subject; and
determining an increased potential that the patient is predisposed for developing stretch marks when the sample of dermal tissue from said human patient has at least 36% less total extracellular matrix protein content and at least 16% less total fibroblast DNA content than the normal dermal tissue from said control subject.
2. The method of claim 1 , wherein the total extracellular matrix protein is selected from elastin, collagen, fibrillin or a combination thereof.
3. The method of claim 1 further comprising:
establishing a rate of proliferation for fibroblasts for nominal dermal tissue from a control human subject;
determining a rate of proliferation for fibroblasts from said sample of dermal tissue from said human patient;
comparing the rate of proliferation for fibroblasts from said sample of dermal tissue from said patient with the rate of proliferation for fibroblasts for normal dermal tissue from said control subject; and
determining an increased potential that the patient is predisposed for developing stretch marks when the sample of dermal tissue from the patient has a lower rate of fibroblast proliferation than the normal dermal tissue.
4. The method of claim 1 further comprising:
establishing a rate of migration for fibroblasts for normal dermal tissue from a control human subject;
determining a rate of migration for fibroblasts from said sample of dermal tissue from said human patient;
comparing the rate of migration for fibroblasts from said sample of dermal tissue from the patient with the rate of migration for fibroblasts for normal dermal tissue; and
determining an increased potential that the patient is predisposed for developing stretch marks when the sample of dermal tissue from the patient has a lower rate of fibroblast migration than the normal dermal tissue.
5. The method of claim 1 further comprising:
establishing a rate of the total extracellular matrix deposition for fibroblasts for normal dermal tissue from a control human subject;
determining a rate of the total extracellular matrix deposition for fibroblasts from said sample of dermal tissue from said human patient;
comparing the rate of the total extracellular matrix deposition for fibroblasts from said sample of dermal tissue from said patient with the rate of the total extracellular matrix deposition for fibroblasts for normal dermal tissue from said control subject; and
determining an increased potential that the patient is predisposed for developing stretch marks when the sample of dermal tissue from the patient has a lower rate of fibroblast extracellular matrix deposition than the normal dermal tissue.
6. The method of claim 5 , wherein the rate of the total extracellular matrix deposition is the rate of total elastin deposition.
7. The method of claim 6 , wherein the rate of total elastin deposition in the sample of dermal tissue from said human patient does not exceed 30% of the rate of total elastin deposition in the normal dermal tissue sample from said control subject.